(Q40377110)

20 September 2017

title

Standardized allergen extracts: past, present and future (English)

1 reference

20 September 2017

Linda Cox

1

1 reference

20 September 2017

language of work or name

1 reference

1 November 2005

1 reference

Expert Review of Clinical Immunology

20 September 2017

published in

1 reference

20 September 2017

volume

1

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

579-588

1 reference

Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Manufacturing and standardizing fungal allergen products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

The determination of equivalent doses of standardized allergen vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

The CREATE project: EU support for the improvement of allergen standardization in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Recombinant allergens for diagnosis and therapy of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Molecular cloning of a major Alternaria alternata allergen, rAlt a 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Responses to ragweed-pollen nasal challenge before and after immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

FURTHER OBSERVATIONS ON THE TREATMENT OF HAY FEVER BY HYPODERMIC INOCULATIONS OF POLLEN VACCINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen–allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

Immunotherapy with cat- and dog-dander extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.4.579

21 January 2018

Identifiers

DOI

10.1586/1744666X.1.4.579

1 reference

20 September 2017

1 reference